Marion Dorsch

9.0k total citations · 1 hit paper
55 papers, 3.7k citations indexed

About

Marion Dorsch is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Marion Dorsch has authored 55 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 18 papers in Oncology and 17 papers in Immunology. Recurrent topics in Marion Dorsch's work include Epigenetics and DNA Methylation (11 papers), Hedgehog Signaling Pathway Studies (7 papers) and Acute Myeloid Leukemia Research (6 papers). Marion Dorsch is often cited by papers focused on Epigenetics and DNA Methylation (11 papers), Hedgehog Signaling Pathway Studies (7 papers) and Acute Myeloid Leukemia Research (6 papers). Marion Dorsch collaborates with scholars based in United States, Germany and Switzerland. Marion Dorsch's co-authors include Zainab Jagani, Dereck D. Amakye, Hanno Hock, William R. Sellers, Tibor Diamantstein, Frank Stegmeier, Thomas Blankenstein, Christoph Lengauer, Markus Warmuth and Ulrich Kunzendorf and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Marion Dorsch

55 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Unraveling the therapeutic potential of the Hedgehog pathway in cancer

2013 437 citations Zainab Jagani, Marion Dorsch et al. profile →

Peers

Countries citing papers authored by Marion Dorsch

Since Specialization

Citations

This map shows the geographic impact of Marion Dorsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marion Dorsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marion Dorsch more than expected).

Fields of papers citing papers by Marion Dorsch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marion Dorsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marion Dorsch. The network helps show where Marion Dorsch may publish in the future.

Co-authorship network of co-authors of Marion Dorsch

This figure shows the co-authorship network connecting the top 25 collaborators of Marion Dorsch. A scholar is included among the top collaborators of Marion Dorsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marion Dorsch. Marion Dorsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC 2020 ·Annals of Oncology ·Stefanie S. Schalm, (unknown), Sangbin Lim, (unknown), (unknown), Rich Woessner, (unknown), Kevin Wilson, (unknown), Douglas Wilson, Brett Williams, John Campbell, Chris De Savi, Faith Stevison, (unknown), (unknown), Marion Dorsch, Klaus P. Hoeflich, (unknown)	43
2	P2.03-44 BLU-667 Demonstrates Robust Activity in RET Fusion-Driven Intracranial Tumor Models 2019 ·Journal of Thoracic Oncology ·Erica N Evans, Wei Hu, (unknown), Klaus P. Hoeflich, Marion Dorsch	14
3	Differential Aspartate Usage Identifies a Subset of Cancer Cells Particularly Dependent on OGDH 2016 ·Cell Reports ·Eric L. Allen, Danielle Ulanet, David Pirman, Christopher E. Mahoney, (unknown), Yaguang Si, (unknown), Lingling Huang, (unknown), Sung Choe, Michelle Clasquin, Erin Artin, Zi Peng Fan, Giovanni Cianchetta, Joshua Murtie, Marion Dorsch, Shengfang Jin, Gromoslaw A. Smolen	53
4	MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis 2016 ·Cell Reports ·Katya Marjon, Michael J. Cameron, Phong Quang, Michelle Clasquin, Everton Mandley, Kaiko Kunii, (unknown), Sung Choe, Andrew Kernytsky, Stefan Größ, Zenon Konteatis, Joshua Murtie, Michelle Blake, Jeremy Travins, Marion Dorsch, Scott A. Biller, Kevin M. Marks	280
5	A mouse model of a human congenital disorder of glycosylation caused by loss of PMM2 2016 ·Human Molecular Genetics ·Barden Chan, Michelle Clasquin, Gromoslaw A. Smolen, Gavin Histen, (unknown), Yue Chen, Zhi‐Zhong Lin, (unknown), Yan Liu, Yong Cang, (unknown), Yuanfeng Xia, (unknown), Chris Singleton, Marion Dorsch, Lee Silverman, Shinsan M. Su, Hudson H. Freeze, Shengfang Jin	33
6	Mesenchymal Phenotype Predisposes Lung Cancer Cells to Impaired Proliferation and Redox Stress in Response to Glutaminase Inhibition 2014 ·PLoS ONE ·Danielle Ulanet, (unknown), Abhishek Jha, Sung Choe, Ying Wang, (unknown), Mya Steadman, Byron DeLaBarre, Stefan Größ, Edward M. Driggers, Marion Dorsch, Jonathan Hurov	39
7	AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo 2014 ·Blood ·Erica Hansen, Cyril Quivoron, (unknown), René M. Lemieux, Janeta Popovici-Müller, Hossein Sadrzadeh, Amir T. Fathi, Camelia Gliser, Muriel D. David, Véronique Saada, Jean‐Baptiste Micol, Olivier Bernard, Marion Dorsch, Hua Yang, Michael Su, Sam Agresta, Stéphane de Botton, Virginie Penard‐Lacronique, Katharine Yen	40
8	Small Molecule Antagonists in Distinct Binding Modes Inhibit Drug-Resistant Mutant of Smoothened 2011 ·Chemistry & Biology ·Hai‐Yan Tao, Qihui Jin, (unknown), Xuebin Liao, Nathan Englund, Yan Wang, (unknown), Peter G. Schultz, Marion Dorsch, Joseph F. Kelleher, Xu Wu	55
9	The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma Cells 2010 ·Cancer Research ·Zainab Jagani, Dmitri Wiederschain, Alice Loo, Dan He, Rebecca Mosher, Paul Fordjour, John E. Monahan, Michael Morrissey, (unknown), Christoph Lengauer, Markus Warmuth, William R. Sellers, Marion Dorsch	48
10	A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by Culture In vitro 2009 ·Cancer Research ·Vincent C. Daniel, Luigi Marchionni, Jared S. Hierman, Jonathan T. Rhodes, Wendy L. Devereux, Charles M. Rudin, Rex Yung, Giovanni Parmigiani, Marion Dorsch, Craig D. Peacock, D. Neil Watkins	337
11	PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers 2009 ·Cancer Research ·Susan Wee, Zainab Jagani, Kay X. Xiang, Alice Loo, Marion Dorsch, Yung‐Mae Yao, William R. Sellers, Christoph Lengauer, Frank Stegmeier	354
12	Regulation of IRAK-4 kinase activity via autophosphorylation within its activation loop 2006 ·Biochemical and Biophysical Research Communications ·Hong Cheng, Terri A. Addona, Hasmik Keshishian, (unknown), Chafen Lu, Marion Dorsch, Zhi Li, Anlai Wang, Timothy D. Ocain, Ping Li, Thomas F. Parsons, Bruce Jaffee, Yajun Xu	61
13	Ikkepsilon regulates viral-induced interferon regulatory factor-3 activation via a redox-sensitive pathway 2006 ·Virology ·(unknown), Shawn M. Castro, (unknown), (unknown), Marion Dorsch, Anthony J. Coyle, Roberto P. Garofalo, Allan R. Brasier, Antonella Casola	39
14	Validating cancer drug targets 2006 ·Nature ·John D. Benson, (unknown), Susan Cornell-Kennon, Marion Dorsch, Sunkyu Kim, Magdalena Leszczyniecka, William R. Sellers, Christoph Lengauer	104
15	Nucleotide binding to CARD12 and its role in CARD12-mediated caspase-1 activation 2005 ·Biochemical and Biophysical Research Communications ·Chafen Lu, Anlai Wang, Lin Wang, Marion Dorsch, Timothy D. Ocain, Yajun Xu	31
16	Isolation and Characterization of the Notch Ligand Delta4 2000 ·Experimental Cell Research ·Prakash K. Rao, Marion Dorsch, Troy W. Chickering, Gang Zheng, (unknown), Andrew Goodearl, Tom Kadesch, Sean A. McCarthy	53
17	Increased sensitivity to apoptotic stimuli in c-abl-deficient progenitor B-cell lines 1996 ·Proceedings of the National Academy of Sciences ·Marion Dorsch, Stephen P. Goff	24
18	Gene transfer of the interleukin (IL)‐2 receptor β chain into an IL‐7‐dependent pre‐B cell line permits IL‐2‐driven proliferation: Tyrosine phosphorylation of Shc is induced by IL‐2 but not IL‐7 1994 ·European Journal of Immunology ·Marion Dorsch, Hanno Hock, Tibor Diamantstein	16
19	Macrophage colony‐stimulating factor gene transfer into tumor cells induces macrophage infiltration but not tumor suppression 1993 ·European Journal of Immunology ·Marion Dorsch, Hanno Hock, Ulrich Kunzendorf, Tibor Diamantstein, Thomas Blankenstein	42
20	Interleukin 7 induces CD4+ T cell-dependent tumor rejection. 1991 ·The Journal of Experimental Medicine ·Hanno Hock, Marion Dorsch, Tibor Diamantstein, Thomas Blankenstein	200

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact